Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hypogonadism Clinical Trials

A listing of Hypogonadism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (41) clinical trials

Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism

The study will be conducted in male subjects from 18 to 80 years of age requiring testosterone replacement therapy for primary or secondary hypogonadism. The study is a randomised, active control, single dose, 2-way cross-over study in 2 cohorts. In each cohort subjects who meet the entry criteria at screening ...

Phase

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Please contact study staff for a detailed description.

Phase

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

After age of 40, testosterone (T) production in men gradually decreases at a rate of 1.6% per year for total and to 2-3% per year for bioavailable T. This reduction in T production in men parallels the age-associated loss of muscle mass that leads to sarcopenia and impairment of function ...

Phase

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22). Treatment with pembrolizumab / maraviroc combination will continue until progressive disease (PD), unacceptable adverse events (AEs), intercurrent illness that ...

Phase

Testosterone Therapy in Hypogonadal Men Treated With Opioids

The study duration is 24 weeks. Patients are treated with Testosterone Undecanoate 1000 mg/4 ml, intramuscular (i.m.) or placebo at 0, 6 and 18 weeks. Outcome measures will be evaluated at 0 and 14 weeks.

Phase

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.

Phase

Administration of Kisspeptin to Subjects With Reproductive Disorders

The master reproductive hormone GnRH (gonadotropin-releasing hormone) is essential for normal reproductive function. People with hypogonadotropic hypogonadism (IHH), hyperprolactinemia, and polycystic ovarian syndrome (PCOS) do not secrete or respond to GnRH in a normal way. In this study, investigators will give participants, kisspeptin a hormone that is naturally found in ...

Phase

Kisspeptin in the Evaluation of Delayed Puberty

Some children with delayed puberty will eventually enter puberty on their own. However, some children with delayed puberty have a permanent condition and require medical treatment to undergo puberty. Right now, there is no reliable diagnostic tool to tell whether a child's delayed puberty will be self-resolving or permanent. The ...

Phase

Neuropeptides in Human Reproduction

The investigators are seeking healthy volunteers and volunteers with reproductive disorders for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally occurring opioid hormone that is blocked by naloxone. We hypothesize that naloxone, by blocking dynorphin, will stimulate production of GnRH and kisspeptin, 2 ...

Phase

Kisspeptin Influence on Glucose Homeostasis

This study examines how a naturally occurring peptide called Kisspeptin might regulate blood sugar and insulin levels.

Phase